Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.

Marketwired October 6, 2014

EQUITY ALERT: The Rosen Law Firm P.A. Announced Filing of Securities Class Action Against AcelRx Pharmaceuticals, Inc. - ACRX

GlobeNewswire October 6, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX

GlobeNewswire October 6, 2014

Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting

PR Newswire October 6, 2014

INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith

Business Wire October 3, 2014

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm

PR Newswire October 3, 2014

INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP

Business Wire October 2, 2014

SHAREHOLDER ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Investors Announced by Law Offices of Howard G. Smith

Business Wire September 29, 2014

INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP

Business Wire September 29, 2014

AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso(TM)

PR Newswire September 26, 2014

AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids

PR Newswire September 10, 2014

AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results

PR Newswire September 4, 2014

AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events

PR Newswire August 27, 2014

AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results

PR Newswire August 11, 2014

AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events

PR Newswire August 8, 2014

AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.

PR Newswire August 7, 2014

AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso(TM)

PR Newswire July 25, 2014

AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso

PR Newswire July 24, 2014

AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO(TM)

PR Newswire July 7, 2014

NeoChord appoints David Chung as President and CEO

Business Wire June 24, 2014